John P. Butler - 02 Feb 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
CEO and President, Director
Signature
/s/ Carolyn M. Rucci, attorney-in-fact for John P. Butler
Issuer symbol
AKBA
Transactions as of
02 Feb 2026
Net transactions value
-$227,311
Form type
4
Filing time
04 Feb 2026, 16:10:28 UTC
Previous filing
03 Feb 2026
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Butler John P. CEO and President, Director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE /s/ Carolyn M. Rucci, attorney-in-fact for John P. Butler 04 Feb 2026 0001591467

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale $64,857 -46,660 -1.3% $1.39 3,417,189 02 Feb 2026 Direct F1, F2
transaction AKBA Common Stock Sale $133,530 -96,065 -2.8% $1.39 3,321,124 02 Feb 2026 Direct F2, F3
transaction AKBA Common Stock Sale $159,698 -114,891 -3.5% $1.39 3,206,233 02 Feb 2026 Direct F2, F4
transaction AKBA Common Stock Award $247,102 +175,250 +5.5% $1.41 3,381,483 02 Feb 2026 Direct F5
transaction AKBA Common Stock Sale $116,328 -83,689 -2.5% $1.39 3,297,794 02 Feb 2026 Direct F2, F6
holding AKBA Common Stock 159,928 02 Feb 2026 Held by Dorothy Butler Revocable Trust November 20, 2007
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.
F2 This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.
F3 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
F4 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.
F5 As reported in February 2025, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2023 Stock Incentive Plan, as amended. Each PSU right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs vests on the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period (the "Stock Price Hurdle 1 Performance Condition"), subject to the reporting persons continuous employment through the applicable vesting date. In July2025, the Compensation Committee certified that the Stock Price Hurdle 1 Performance Condition was met during the performance period and therefore one-half of the PSUs vested on January 31, 2026.
F6 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's performance stock units granted on January 31, 2025.